<DOC>
	<DOCNO>NCT00660816</DOCNO>
	<brief_summary>RATIONALE : Pemetrexed disodium erlotinib hydrochloride may stop growth tumor cell block enzymes need cell growth . Drugs use chemotherapy , docetaxel , work different way stop growth tumor cell , either kill cell stop dividing . It yet know whether give pemetrexed disodium docetaxel together erlotinib hydrochloride effective give pemetrexed disodium docetaxel alone treat non-small lung cancer . PURPOSE : This randomized phase II trial study well give pemetrexed disodium docetaxel together without erlotinib hydrochloride work treat patient stage IIIB stage IV non-small cell lung cancer .</brief_summary>
	<brief_title>Pemetrexed Docetaxel With Without Erlotinib Stage IIIB Stage IV Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To evaluate whether maintenance erlotinib hydrochloride add standard care ( pemetrexed disodium docetaxel ) chemotherapy patient erlotinib hydrochloride-responsive advanced non-small cell lung cancer lead improve progression-free survival compare standard care pemetrexed disodium docetaxel alone . Secondary - To evaluate effect maintenance erlotinib hydrochloride response rate standard care ( pemetrexed disodium docetaxel ) therapy patient erlotinib hydrochloride-responsive advanced non-small cell lung cancer compare standard care ( pemetrexed disodium docetaxel ) alone . - To evaluate whether maintenance erlotinib hydrochloride add standard care ( pemetrexed disodium docetaxel ) chemotherapy patient erlotinib hydrochloride-responsive advanced non-small cell lung cancer lead improve overall survival compare standard care ( pemetrexed disodium docetaxel ) alone . - To evaluate effect maintenance erlotinib hydrochloride disease stabilization ( complete response [ CR ] + partial response [ PR ] + stable disease [ SD ] ) rate standard care ( pemetrexed disodium docetaxel ) therapy patient erlotinib hydrochloride-responsive advanced non-small cell lung cancer compare standard care ( pemetrexed disodium docetaxel ) alone . - To evaluate utility early positron emission tomography ( PET ) scanning ( baseline versus 1 cycle protocol therapy ) overall disease assessment prediction treatment responsiveness . OUTLINE : This multicenter , randomize study . Patients stratify accord lifetime smoking status ( never vs ever ) ECOG performance status ( 0-1 v â‰¥ 2 ) . Patients randomize 1 2 treatment arm . - Arm I : ( standard care alone ) : Patients receive pemetrexed disodium intravenously ( IV ) 10 minute OR docetaxel IV 60 minute day 1 . Treatment repeat every 21 day 8 course absence disease progression unacceptable toxicity . - Arm II : ( standard care plus erlotinib ) : Patients receive pemetrexed disodium IV 10 minute OR docetaxel IV 60 minute day 1 erlotinib hydrochloride orally ( PO ) daily day 2-19 . Treatment repeat every 21 day 8 course absence disease progression unacceptable toxicity . Patients may continue receive standard chemotherapy without erlotinib hydrochloride absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 8 week .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>INCLUSION CRITERIA Pathologic diagnosis stage IIIB ( pleural effusion ) IV nonsmall cell lung cancer Progression follow least twelve week treatment singleagent erlotinib ( combination experimental agent ) time patient experience clinical benefit assess his/her treat physician corroborate radiographic assessment ( least one CT scan follow least 4 week erlotinib monotherapy demonstrate stable disease response erlotinib therapy ) . At least one measurable lesion define modify Response Evaluation Criteria In Solid Tumors ( RECIST ) criterion Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Life expectancy least 12 week Absolute neutrophil count ( ANC ) &gt; = 1.5x10 ( 9 ) /L Platelet count &gt; = 100x 10 ( 9 ) Hemoglobin &gt; = 8.0 g/dl Serum creatinine = &lt; 1.5 upper limit normal OR calculate creatinine clearance &gt; = 45 mL/min Total bilirubin = &lt; 1.5 x upper limit normal ( ULN ) Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) = &lt; 2.5 x ULN Available baseline diagnostic tumor specimen correlative study , diagnostic material acceptable paraffin block , cell block , fine needle aspirate etc . Patients must provide verbal write informed consent participate study Willingness ability comply schedule visit , treatment plan , laboratory test , study procedure Patient must able take folic acid , vitamin B12 well dexamethasone therapy per protocol guideline Patient must able interrupt nonsteroidal antiinflammatory drug ( NSAIDs ) 2 day ( 5 day longacting NSAIDs ) , day , 2 day follow administration pemetrexed ( exclusion criterion apply patient receive pemetrexed chemotherapy prior ) EXCLUSION CRITERIA Active central nervous system disease ( CNS ) metastases , indicate clinical symptom , cerebral edema progressive growth ( subject clinical history CNS metastases cord compression allowable definitively treat clinically stable least 4 week first dose study treatment prior whole brain radiation 2 week prior gamma knife therapy ) More 1 prior cytotoxic chemotherapy regimen relapse metastatic disease ( include erlotinib ) Any prior epidermal growth factor receptor ( EGFR ) inhibitor therapy except erlotinib Major surgery , chemotherapy , investigational agent within 3 week treatment day 1 ( except erlotinib ) . Radiation therapy within 2 week treatment day 1 ( except erlotinib ) . Prior treatment pemetrexed docetaxel chemotherapy Pregnancy breastfeed receive adequate contraception ( include patient spouse ) Other severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation study drug administration may interfere interpretation study result , judgment investigator would make patient inappropriate entry study Patients must receive pemetrexed presence third space fluid control drainage Patients must receive docetaxel peripheral neuropathy &gt; grade 2 Patients must receive docetaxel hypersensitivity reaction medication formulate polysorbate 80</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
</DOC>